Ferring Announces Recipients of Innovation Grants Program 2017-2018
Ferring Pharmaceuticals today announced the recipients of the 2017-2018 Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego. This global program supports research in the fields of reproductive medicine and women’s health, urology, gastroenterology, hepatology, and endocrinology.
“The quality of applications received in response to the 2017-2018 Ferring Innovation Grants call for proposals was outstanding. We have funded programs that we believe represent the leading edge of research in their therapeutic fields, and very much look forward to seeing the outcome of the innovative projects proposed by this year’s grant awardees,” said Keith James, President Ferring Research Institute, Senior Vice President Research and Development.
Now in its fifth year, the Innovation Grants Program received 300 submissions. Each submission was reviewed for its scientific merit, and a short list of finalists were invited to submit more detailed applications for consideration. A total of 13 projects were chosen to receive grant funding from Ferring this year. In addition to the United States, projects have been funded in Canada, the United Kingdom, Australia, and Portugal. This year’s recipients, together with the grant titles, are:
Stéphane Bolduc - CHU de Québec - Université Laval Research
Identify protein(s) secreted by urothelial cell carcinoma (UCC) involved in modification of tumor-associated stroma by activation of Cancer-Associated Fibroblasts (CAF).
Marcello Costa - Flinders University
Enteric neuropeptides modulation of colonic motility in health and disease
Warren Foster - McMaster University
Evaluation of a novel therapeutic intervention for the management of endometriosis in a mouse model
Andrew Horne - University of Edinburgh
Targeting TGFβ-1 with an extracellular peptide inhibitor to treat women with peritoneal endometriosis
K. Joseph Hurt - University of Colorado School of Medicine
Adiponectin receptor regulation of myometrial contractility suggests novel therapeutic targets to augment uterine quiescence and prevent preterm birth
Ursula Kaiser - Brigham and Women's Hospital, Harvard Medical
Differential modulation of LH and FSH by GnRH analogs for improved treatment of reproductive disorders
Sarah Marshall - Monash University
Exploring novel therapies for preeclampsia: the role of soluble prorenin receptor on vasculature function
Kathryn Meier - Washington State University
FSH receptor as a therapeutic target in prostate cancer
Victor Navarro - Brigham and Women's Hospital, Harvard Medical
Targeting the Kappa Opioid Receptor to Regulate LH Pulses in PCOS Patients
Willis Samson - Saint Louis University School of Medicine
A Novel Ligand (Adropin) – Receptor (GPR19) Handshake: Implications for the Control of Growth Hormone Secretion
John Taylor - Kansas University Medical Center
The Role of d-Dopachrome Tautomerase in Bladder Cancer Tumorigenesis
Suraj Unniappan - University of Saskatchewan
Nesfatin-1 and Nesfatin-1-Like Peptide Regulation of Growth and Stress Hormones: Novel Targets for Endocrine Diseases
Henrique Veiga-Fernandes - Champalimaud Foundation
Activation of type 3 Innate Lymphoid Cells and innate IL-22 secretion via RET signaling for Inflammatory Bowel Disease treatment
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 7,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
About Ferring Research Institute Inc:
Located in San Diego, California Ferring Research Institute Inc. (FRI) is a global therapeutics research center for Ferring Pharmaceuticals. FRI is committed to delivering a pipeline of innovative therapies which improve the lives of patients in the areas of reproductive medicine and women’s health, urology, gastroenterology and hepatology. For more detailed information please visit www.ferring-research.com .
Ferring Corporate Communications Team:
Senior Manager, Corporate Communications
+41 58 451 40 23 (direct)
+41 79 191 0486 (mobile)
Head of Corporate Communications
+41 58 301 09 52 (direct)
+41 79 191 06 32 (mobile)
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
SM-Optics Unveils First FLEXSET Chip, Paving the Way to Optical Micro Nodes23.2.2018 14:00 | Pressemelding
SM-Optics launches FLEXSET, a single chip embedding multiple processing functionalities raising the bar for performances, density and architectural flexibility. The FLEXSET is the heart of the Lightmode product family. FLEXSET OTN switching matrix scales from 300Gbps to 1Tbps and can be addressed by ports spanning from traditional low-speed services like 2Mbps over micro-OTN, to layer2 and layer3 over ODUFlex, 100G over ODU4 and 200G over FlexO. Thanks to its embedded capabilities including multi-technology OAM, packet processing, synchronization and fast protection functions, FLEXSET operates by design at the lowest latency performances and features an Intel Stratix 10 FPGA. Following the launch of micro-OTN, a revolutionary approach to efficiently extend OTN protocol to low speed services, the launch of FLEXSET advances the vision of a highly interconnected metro network and of micro nodes. Revolving around functional block elements, micro nodes collapse in few rack units OTN and pho
Bitcoin Miner HashGains’ Crowdsale to Build Green Cloud Mining Data Centers Receives Excellent Response23.2.2018 13:56 | Pressemelding
HashGains.com, a leading cryptocurrency mining platform, has launched its crowdsale program to build mega cryptocurrency cloud mining data centers in India and Canada which uses renewable energy like wind and solar as source of energy. “With the growing worries around bitcoin mining causing environmental damage, difficulty levels of mining increasing and returns heading southwards, there was no better opportunity but to build green energy data centers which run on free sources of energy like wind and solar, ensuring handsome mining rewards while taking care of environment,” said Mr Anuj Bairathi, CEO & Founder, HashGains, who is crypto enthusiast himself. HashGains is a growing cloud mining platform with more than 10,000 active customers enjoying mining returns and is expected to reach the mark of 1 million customers by 2020. To handle such a massive growth and ever growing demand of customers, it becomes even more important that mega mining centers are planned which can serve needs of
Stratecast Recognizes CARDINALITY as a “10 to Watch in 2018”23.2.2018 13:07 | Pressemelding
In their new report, “Digital Transformation Means New Tools for New Business” —part of the Global Operations, Orchestration, Data Analytics, and Monetisation (ODAM) stream—Stratecast recognises CARDINALITY for their new approach towards processing big data to deliver applications such as Customer Experience, Operational Intelligence, Network Analytics, Churn Management and Marketing Intelligence. Stratecast identified that the CARDINALITY Perception Platform brings large amounts of data from multiple CSP sources together in order to address a growing group of data analysis needs from different operational work teams and the wider business. It also does this at ingestion rates and storage levels previously thought not practical. "Using design principals tied to microservices and containerized solution components, the platform is a major advancement in meeting CSP data analysis needs at a price untouchable by previously-defined platforms," said Karl Whitelock, Stratecast director of glo
IBC2018 Welcomes Channel 4’s Keith Underwood as Guest Chair of Content Steering Group23.2.2018 11:03 | Pressemelding
IBC is thrilled to announce that Keith Underwood, Director of Strategy and Technology at Channel 4, has accepted the role of Guest Chair of the Conference for IBC2018. The position involves acting as the figurehead and brand ambassador for IBC, setting the vision for the programme and increasing awareness and engagement with IBC across both traditional and converging media markets. Keith is the Channel 4 Executive Committee member responsible for strategy and corporate development, broadcast operations, content management, corporate systems and the development of Channel 4’s digital products. His achievements at the public broadcaster include the launch of All 4, Channel 4’s award-winning video on demand service that replaced 4oD in 2015. “The media industry is experiencing profound shifts in consumer behaviour, competitive dynamics, and technological innovation.” Keith Underwood said. “Relentless disruption of established business models presents new opportunities and challenges for p
SES S.A.: Full Year and Fourth Quarter 2017 Results23.2.2018 07:00 | Pressemelding
SES S.A. announced financial results for the year and three months ended 31 December 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222006522/en/ Full Year and Fourth Quarter 2017 Results (Photo: Business Wire) Key financial highlights Reported revenue EUR 2,035.0 million, down 1.6% (-5.2% like-for-like(1)); SES Video -3.6%(1) and SES Networks -1.9%(1) EBITDA margin 65.1% (2016: 70.2% as reported and 66.7% like-for-like(1)) Net profit of EUR 596.1 million (2016: EUR 962.7 million including EUR 495.2 million gain related to O3b consolidation) Board is proposing 2017 dividend per A share of EUR 0.80 (2016: EUR 1.34) Change (%) Change (%) EUR million FY 2017 FY 2016 Reported Like-for-like (1) Q4 2017 Q4 2016 Reported Like-for-like (1) Revenue 2,035.0 2,068.8 -1.6% -5.2% 507.8 578.7 -12.2% -8.7% EBITDA 1,324.2 1,451.5 -8.8% -7.6% 329.6 390.6 -15.6% -12.2% EBITDA margin 65.1% 66.7%(1) 64.9% 67.6%(1) Operating profit (2) 6
Lion/Gem Luxembourg 3 S.a.r.l. Announce First Quarter Results for FY 201823.2.2018 07:00 | Pressemelding
The First Quarter results for FY18 for Lion/Gem Luxembourg 3 S.a.r.l. (associated with Young’s Seafood Limited) will be made available on our Investor Relations website on February 23, 2018. The First Quarter results call for investors that accompanies this information is scheduled to take place at 13:00 GMT on February 23, 2018. The First Quarter covers the quarter to 30 December 2017; the financial year end for Lion/Gem Luxembourg 3 S.a.r.l. is September 30, 2018. For further information: If you are an investor or a potential investor in the 8¼%/ 9% Senior PIK Notes due 2019, of Lion/Gem Luxembourg 3 S.a.r.l., and would like access to this information, please register your interest on our Investor Relations website: https://youngsseafood.co.uk/investors/. If you have any questions about the registration process or need further information, please do not hesitate to contact Nicholas Donnelly, Communications Manager at Young’s Seafood: firstname.lastname@example.org This announc